ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,883,996 | +19.5% | 108,948 | +54.7% | 0.00% | +100.0% |
| Q2 2023 | $3,249,628 | +10537.1% | 70,445 | -90.8% | 0.00% | -94.4% |
| Q1 2023 | $30,550 | -14.7% | 761,847 | -1.4% | 0.02% | -10.0% |
| Q4 2022 | $35,800 | -99.7% | 772,727 | +161.6% | 0.02% | +185.7% |
| Q3 2022 | $12,233,000 | +65.6% | 295,402 | +138.6% | 0.01% | +40.0% |
| Q2 2022 | $7,388,000 | +1270.7% | 123,831 | +1569.3% | 0.01% | – |
| Q1 2022 | $539,000 | -89.9% | 7,418 | -88.3% | 0.00% | -100.0% |
| Q4 2021 | $5,318,000 | -45.3% | 63,240 | -41.3% | 0.00% | -50.0% |
| Q3 2021 | $9,719,000 | -81.9% | 107,764 | -80.9% | 0.01% | -81.8% |
| Q2 2021 | $53,719,000 | +625.8% | 563,387 | +766.7% | 0.03% | +560.0% |
| Q1 2021 | $7,401,000 | +468.9% | 65,000 | +591.9% | 0.01% | +400.0% |
| Q4 2020 | $1,301,000 | +166.1% | 9,395 | +57.8% | 0.00% | 0.0% |
| Q3 2020 | $489,000 | -88.7% | 5,953 | -89.3% | 0.00% | -83.3% |
| Q2 2020 | $4,343,000 | +629.9% | 55,523 | +314.5% | 0.01% | +500.0% |
| Q1 2020 | $595,000 | +139.9% | 13,394 | +130.4% | 0.00% | – |
| Q3 2019 | $248,000 | -81.3% | 5,813 | -66.5% | 0.00% | -100.0% |
| Q3 2018 | $1,325,000 | -91.3% | 17,362 | -94.2% | 0.00% | -90.0% |
| Q1 2018 | $15,310,000 | +166.6% | 300,260 | +142.5% | 0.02% | +150.0% |
| Q4 2017 | $5,743,000 | +24.6% | 123,835 | +43.1% | 0.01% | +14.3% |
| Q3 2017 | $4,608,000 | +1632.3% | 86,520 | +2107.1% | 0.01% | – |
| Q1 2017 | $266,000 | -62.5% | 3,920 | -60.8% | 0.00% | -100.0% |
| Q3 2016 | $709,000 | -96.9% | 10,000 | -97.8% | 0.00% | -98.1% |
| Q2 2016 | $22,559,000 | +24.6% | 461,245 | +61.3% | 0.05% | +15.6% |
| Q1 2016 | $18,100,000 | -16.9% | 285,895 | +47.2% | 0.04% | -2.2% |
| Q4 2015 | $21,784,000 | -58.2% | 194,190 | -64.2% | 0.05% | -54.5% |
| Q3 2015 | $52,170,000 | +5.2% | 541,689 | +11.9% | 0.10% | +7.4% |
| Q2 2015 | $49,575,000 | -18.7% | 484,180 | -50.7% | 0.09% | -16.8% |
| Q1 2015 | $60,963,000 | +352.1% | 981,846 | +219.5% | 0.11% | +289.7% |
| Q4 2014 | $13,484,000 | +5866.4% | 307,283 | +7582.1% | 0.03% | +2800.0% |
| Q3 2014 | $226,000 | -64.9% | 4,000 | -72.1% | 0.00% | -50.0% |
| Q2 2014 | $644,000 | -83.1% | 14,350 | -81.6% | 0.00% | -81.8% |
| Q1 2014 | $3,820,000 | – | 78,131 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |